Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery

Cancer Lett. 2007 Mar 8;247(1):130-6. doi: 10.1016/j.canlet.2006.03.029. Epub 2006 May 4.


Preventing peritoneal implantation of ovarian carcinoma cells could prolong patient remission and survival. CA125 is expressed on most ovarian cancer cells and was reported to be a ligand of mesothelin, a peritoneal protein. We developed a cell adhesion assay with CA125-expresser ovarian cancer cells and human mesothelin-transfected cells and we confirmed that CA125 and mesothelin mediate cell attachment. We also showed that this assay supplies a high-throughput screening system for reagents able to block CA125/mesothelin-dependent cell attachment with a sensitive quantitative readout. We finally demonstrated that a mesothelin chimeric protein and anti-CA125 antibodies block CA125/mesothelin-dependent cell attachment.

Publication types

  • Evaluation Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / pharmacology
  • Biomarkers, Tumor
  • CA-125 Antigen / immunology
  • CA-125 Antigen / metabolism*
  • Cell Adhesion*
  • Cell Line, Tumor
  • Drug Screening Assays, Antitumor*
  • Female
  • GPI-Linked Proteins
  • Humans
  • Membrane Glycoproteins / genetics
  • Membrane Glycoproteins / metabolism*
  • Mesothelin
  • Ovarian Neoplasms / pathology*
  • Peritoneal Neoplasms / prevention & control
  • Peritoneal Neoplasms / secondary
  • Transfection


  • Antibodies, Monoclonal
  • Biomarkers, Tumor
  • CA-125 Antigen
  • GPI-Linked Proteins
  • Membrane Glycoproteins
  • Mesothelin

Associated data

  • RefSeq/NM_005823
  • RefSeq/NM_013404